دورية أكاديمية

Pharmacological activation of insulin‐degrading enzyme improves insulin secretion and glucose tolerance in diet‐induced obese mice.

التفاصيل البيبلوغرافية
العنوان: Pharmacological activation of insulin‐degrading enzyme improves insulin secretion and glucose tolerance in diet‐induced obese mice.
المؤلفون: Sanz‐González, Alba, Cózar‐Castellano, Irene, Broca, Christophe, Sabatier, Julia, Acosta, Gerardo A., Royo, Miriam, Hernándo‐Muñoz, Carla, Torroba, Tomás, Perdomo, Germán, Merino, Beatriz
المصدر: Diabetes, Obesity & Metabolism; Nov2023, Vol. 25 Issue 11, p3268-3278, 11p
مصطلحات موضوعية: INSULIN, ENZYME activation, SECRETION, GLUCOSE, TYPE 2 diabetes, INSULIN sensitivity
مستخلص: Aim: To investigate the use of synthetic preimplantation factor (sPIF) as a potential therapeutic tool for improving glucose‐stimulated insulin secretion (GSIS), glucose tolerance and insulin sensitivity in the setting of diabetes. Materials and Methods: We used a preclinical murine model of type 2 diabetes (T2D) induced by high‐fat diet (HFD) feeding for 12 weeks. Saline or sPIF (1 mg/kg/day) was administered to mice by subcutaneously implanted osmotic mini‐pumps for 25 days. Glucose tolerance, circulating insulin and C‐peptide levels, and GSIS were assessed. In addition, β‐cells (Min‐6) were used to test the effects of sPIF on GSIS and insulin‐degrading enzyme (IDE) activity in vitro. The effect of sPIF on GSIS was also tested in human islets. Results: GSIS was enhanced 2‐fold by sPIF in human islets ex vivo. Furthermore, continuous administration of sPIF to HFD mice increased circulating levels of insulin and improved glucose tolerance, independently of hepatic insulin clearance. Of note, islets isolated from mice treated with sPIF exhibited restored β‐cell function. Finally, genetic (shRNA‐IDE) or pharmacological (6bK) inactivation of IDE in Min‐6 abolished sPIF‐mediated effects on GSIS, showing that both the protein and its protease activity are required for its action. Conclusions: We conclude that sPIF is a promising secretagogue for the treatment of T2D. [ABSTRACT FROM AUTHOR]
Copyright of Diabetes, Obesity & Metabolism is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:14628902
DOI:10.1111/dom.15225